MAAT033

MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study

Retrieved on: 
Monday, January 24, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biomarker, Euronext Paris, Survival, Forward-looking statement, Patient, Human, Degenerative disease, Safety, Incidence, MET, CIMON, OTU, Operational taxonomic unit, Maat, CEO, Data monitoring committee, Acute myeloid leukemia, Bacteria, Graft-versus-host disease, Enema, Company, 16S, CGMP, MD, Capsule, Cancer, Pharmaceutical industry, Dietary supplement, Antibiotics, MaaT033, MaaT Pharma, MAAT033, MAAT PHARMA

Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.

Key Points: 
  • Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.
  • These interim results are an important milestone for MaaT Pharma as MaaT033 is our second drug candidate and our first oral formulation, to demonstrate proof of engraftment in humans, said Herv Affagard, CEO and co-founder of MaaT Pharma.
  • MaaT033 is intended to improve survival outcomes in hemato-oncology patients receiving allo-HSCT by protecting and restoring their gut microbiome.
  • We look forward to further exploring the data from CIMON and preparing for a Phase 2/3 trial start.

MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy

Retrieved on: 
Monday, June 28, 2021
Oncology, Health, Clinical trials, Research, Science, Biotechnology, Health sciences, Health, Clinical research, Medical research, Clinical trials, Pharmaceutical industry, DSMB, Data monitoring committee, Dose-ranging study, MaaT033, MaaT Pharma, MAAT033, MAAT PHARMA

MaaT Pharma , a clinical-stage biotechnology company focused on developing Microbiome Ecosystem Therapies in oncology, today announced that the Data Safety and Monitoring Board (DSMB) recommended to proceed to the fourth cohort of the dose-finding Phase 1b CIMON clinical trial, without modifications.

Key Points: 
  • MaaT Pharma , a clinical-stage biotechnology company focused on developing Microbiome Ecosystem Therapies in oncology, today announced that the Data Safety and Monitoring Board (DSMB) recommended to proceed to the fourth cohort of the dose-finding Phase 1b CIMON clinical trial, without modifications.
  • The DSMB is an independent committee monitoring the progress of the companys clinical trial and is reviewing safety, tolerability and data quality while the trial is ongoing.
  • The CIMON Phase 1b trial is expected to be completed at the end of 2021.
  • MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.